New Breast Cancer Marker: ER Status as a Spectrum, Not Yes/No

New research suggests breast cancer treatment could get a lot smarter by measuring estrogen receptor (ER) status as a continuous spectrum, not just positive or negative. The exact percentage of ER positivity directly influences how well treatments work and a patient's prognosis. This shifts how doctors might target therapies, moving past a simple binary.